AgeX Therapeutics

@agexthera

startup in emerging field of interventional │founder/CEO │VP R/Ts ≠ Endorsement

Vrijeme pridruživanja: lipanj 2017.

Tweetovi

Blokirali ste korisnika/cu @agexthera

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @agexthera

  1. Prikvačeni tweet
    26. tra 2019.

    AgeX and our founder & CEO are included in this cover story Special Report from New Scientist magazine: "A Cure for Ageing" Available on newsstands now, worldwide.

    Poništi
  2. 30. sij

    . covers AgeX and its Collaboration with Japanese Biopharma Company to Generate Hypoimmunogenic Cells (Subscription paywall)

    Poništi
  3. proslijedio/la je Tweet
    30. sij
    Poništi
  4. 29. sij

    AgeX's VP of New Tech Disc is on a panel on the new book by tomorrow (Thur 1/30) . Other panelists are Walter, Cynthia Kenyon , & Moderated by contributor

    Poništi
  5. proslijedio/la je Tweet
    29. sij

    collaborates with announces a collaboration with an as-yet-undisclosed co. to further development of its techn platform.

    Poništi
  6. 29. sij

    2/2 > Secures milestone collaboration in , where R&D is advancing rapidly in a favourable regulatory and commercial environment > UniverCyte platform has potential to deliver cells as therapeutics that do not require immunosuppressive therapy

    Prikaži ovu nit
    Poništi
  7. 29. sij

    1/2 AgeX Therapeutics Enters Research Collaboration w/ Japanese Biopharma Company to Generate Hypoimmunogenic Cells > 1st collaboration for UniverCyte technology platform, marking launch of new business development and collaboration strategy

    Prikaži ovu nit
    Poništi
  8. 17. sij

    AgeX Therapeutics Presenting at Four Conferences this month: > , Jan 13-15 during > PMWC 2020 Jan 21-24 > World Stem Cell Summit Jan 21-24 > Therapeutics Jan 28-30

    Poništi
  9. proslijedio/la je Tweet
    17. sij

    Innovation for Age-related Disease Treatments . Listen to here: Subscribe and review our Podcast on iTunes:

    Poništi
  10. 10. pro 2019.

    Watch a video of AgeX's founder & CEO Dr. Michael West explaining the significance of the new patent related to iPSCs

    Poništi
  11. 10. pro 2019.

    The New patent, No. 10,501,723, has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka on iPSCs, for which he won the for Physiology or Medicine in 2012.

    Poništi
  12. 10. pro 2019.

    AgeX Therapeutics & Lineage Cell Therapeutics Announce Issuance of US Patent for Method of Generating Induced Pluripotent Stem Cells ()

    Poništi
  13. 9. pro 2019.

    AgeX Therapeutics Issues Year-End Letter to Shareholders

    Poništi
  14. 11. lis 2019.
    Poništi
  15. 9. ruj 2019.

    AgeX Therapeutics Presents at the Rodman & Renshaw / HC Wainwright Global Investment Conference

    Poništi
  16. 15. kol 2019.

    2/2 > Begins work using to engineer pluripotent w/ immune tolerance UniverCyte tech to generate hypoimmunogenic (universal) cells. > CEO featured in cover story Special Report in magazine, “A Cure for Aging?”

    Prikaži ovu nit
    Poništi
  17. 15. kol 2019.

    1/2 AgeX Reports Q2 2019 Financial Results & Provides Business Update Highlights include: > Moves into new R&D facility: ≈15,700 sf, inc cGMP-capable manufacturing suite > Strengthens BOD w/ appt of Dr. Michael H. May, CEO of (cont)

    Prikaži ovu nit
    Poništi
  18. 13. kol 2019.

    Regenerative Medicine Leader Dr. Michael H. May Joins AgeX Board of Directors > Serves at President & CEO of Canada’s Centre for Commercialization of Regenerative Medicine (CCRM)

    Poništi
  19. 9. srp 2019.

    AgeX Therapeutics’ CEO to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 11-12 in NYC

    Poništi
  20. 16. svi 2019.

    AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update

    Poništi
  21. 1. svi 2019.

    AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health & Foresight Institute Wednesday, May 1, San Francisco

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·